Oppenheimer concluded: “We came away from the demo more confident that Apple’s hardware ecosystem is safe from new AI-enabled smart glasses for the next 2-3 years. It also gives Apple more runway to ...
Inv esting.com -- Bernstein has initiated coverage of Rightmove (LON:RMV), the UK’s largest property portal, with an “outperform” rating and a price target of 870p, representing a 23% upside from its ...
Gold has rallied 14% since late August to around $3,865, leaving it up 47% year-to-date. The breakout reflects renewed buying from exchange-traded funds (ETFs), central banks, and, to a lesser extent, ...
Investing.com -- Chip stocks gained ground on Thursday following reports that South Korea’s largest companies signed initial agreements to supply chips to OpenAI’s Stargate project, boosting optimism ...
With official employment data, including the all-important nonfarm payrolls report, now likely suspended by the shutdown, Chicago Fed President Austan Goolsbee has suggested that U.S. central bankers ...
Investing.com -- Morgan Stanley raised its price target for Overweight-rated Apple shares to $298 from $240 in a note to clients on Thursday, citing a stronger-than-expected start to the iPhone 17 ...
Investing.com -- HSBC has upgraded Roche Holding AG (SIX:ROG) to “buy” from “hold” in its latest healthcare sector report, raising the target price to CHF320 from CHF285. The upgrade follows key ...
Investing.com -- UBS upgraded its rating on 3i Group (LON:III) to “buy” from “neutral,” raising its price target to £47 from £44.50. Shares of the private equity and venture capital company were up 3% ...
Forvia reiterated its 2025 guidance, targeting a 5.2%-6% operating margin, at least €655 million in net cash flow, and sales of €26.3 billion-€27.5 billion at constant FX. The company confirmed a net ...
In renewables, SSE reported strong output in the second quarter, which offset unfavorable weather conditions in the first quarter. The company expects total first-half renewable generation to reach ...
The brokerage also highlighted that Rational’s Q3 FY25 EBIT margin is assumed at 24.9% versus 25.1% consensus, with reported sales growth projected around 4.5% for 3Q25, compared with 6.2% Bloomberg ...
Eli Lilly and Company, Merck & Company Inc, Biogen Inc, Pfizer Inc. Read 's Market Analysis on Investing.com India ...